生物治疗与个体化诊疗技术前沿——肿瘤免疫临床应用2024-2025秋

描述： 生物治疗是目前恶性肿瘤治疗手段中非常重要的组成部分。生物治疗在临床应用较多的包括CART细胞治疗，免疫检查点抑制剂，免疫检查点抑制剂应用最多的是PD-1/PD-L1抗体。生物/免疫治疗的理论基础，是需要被掌握的内容，这样才能更好地理解药物的作用以及不良反应发生的机制，更好地进行临床应用。目前的生物检测技术在恶性肿瘤的诊断，预后评估以及药物治疗中均有很重要的地位。常见生物/免疫治疗方法有CART细胞、PD-1抗体、等。除了目前的细胞治疗和免疫检查点治疗，还有一些新的生物治疗靶点值得探索研究，并且在未来可能会给肿瘤患者带来获益。我们也要正视生物治疗过程中存在的问题及未来挑战。 Biological therapy is an extremely important component of current malignant tumor treatment methods. Commonly used forms of biological therapy in clinical practice include CART cell therapy, immune checkpoint inhibitors, with PD-1/PD-L1 antibodies being the most widely applied. Understanding the theoretical foundation of biological/immune therapy is crucial in order to better comprehend the mechanism of drug action and the occurrence of adverse reactions, enabling improved clinical applications. Currently, biotechnological techniques hold a significant position in the diagnosis, prognosis evaluation, and drug treatment of malignant tumors. Common biological/immune therapy methods include CART cells and PD-1 antibodies. Apart from current cellular and immune checkpoint therapies, there are other new targets for exploration and research in the field of biological therapy, which may bring benefits to cancer patients in the future. We must also recognize the issues and future challenges present in the process of biological therapy.